About Professor Kim Chan

Professor Chan is a world leader in respiratory drug delivery. Over a decade since joining the University of Sydney, he has developed a leading research program on aerosol drug delivery, ranging from in vitro, ranging from powder production by novel processes, particle engineering and aerosol formulation, to scintigraphic imaging of lung deposition and clinical outcome. He played a pivotal role in the development of Aridol™ (inhaled mannitol for diagnosis of asthma), which was approved by the FDA in the United States, 14 European Union countries, Singapore, Malaysia, South Korea, Australia and New Zealand. He has more than 280 scientific publications on pharmaceutical formulation and drug delivery (including 175 original research papers, 45 book chapters and reviews and 40 full-length conference articles, with over 5,000 citations and H-index of 38) and holds seven patents in these areas.